The placebo effect: Adverse events commonly seen in healthy volunteer phase I drug trials - An observation on findings, comparing active with placebo treatment.

被引：2
|
作者：
Bradford, DA [1 ]
Mant, TG [1 ]
Amin, DA [1 ]
Angell, MP [1 ]
机构：
[1] Quintiles GDRU, London, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(03)90694-1
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P92 / P92
页数：1
相关论文
共 7 条
  • [1] A study of liver transaminases during placebo treatment in phase I drug trials.
    Mathur, A
    Wang, R
    Wallace, D
    Patterson, S
    Mortimer, A
    Brown, L
    Williams, WV
    Ilson, B
    O'Donnell, E
    Fernandez, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P86 - P86
  • [2] THE PLACEBO-EFFECT IN HEALTHY-VOLUNTEERS - INFLUENCE OF EXPERIMENTAL CONDITIONS ON THE ADVERSE EVENTS PROFILE DURING PHASE-I STUDIES
    ROSENZWEIG, P
    BROHIER, S
    ZIPFEL, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (05) : 578 - 583
  • [3] Adverse events during clinical trials comparing leflunomide, methotrexate, sulfasalazine and placebo. meta-analysis of data from phase II and III controlled clinical trials
    Cannon, GW
    Strand, V
    Oed, C
    Scarazzini, L
    Holden, WL
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 252 - 253
  • [4] The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab
    Pincelli, Carlo
    Henninger, Eric
    Casset-Semanaz, Florence
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2006, 298 (07) : 329 - 338
  • [5] The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab
    Carlo Pincelli
    Eric Henninger
    Florence Casset-Semanaz
    Archives of Dermatological Research, 2007, 298 : 329 - 338
  • [6] Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
    Mohraz, Minoo
    Salehi, Mohammadreza
    Tabarsi, Payam
    Abbasi-Kangevari, Mohsen
    Ghamari, Seyyed-Hadi
    Ghasemi, Erfan
    Pouya, Maryam Amini
    Rezaei, Negar
    Ahmadi, Naser
    Heidari, Kazem
    Malekpour, Mohammad-Reza
    Nasiri, Mojtaba
    Amirzargar, Ali Akbar
    Moghaddam, Sahar Saeedi
    Larijani, Bagher
    Hosseini, Hamed
    BMJ OPEN, 2022, 12 (04):
  • [7] Correction: Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults (vol 12 artn e056872, 10.1136/bmjopen-2021-056872 )
    Mohraz, M.
    Salehi, M.
    Tabarsi, P.
    BMJ OPEN, 2022, 12 (11):
1